Filament Health completes ibogaine extraction, begins testing

Filament Health completes ibogaine extraction

Filament Health, a subsidiary of Rhelion Life Sciences Corp., has successfully completed a new extraction of its naturally derived ibogaine drug candidate, IBEX011. The company, based in Toronto, Ontario, is now set to commence stability testing on the new extract, according to a recent announcement.

Stability testing to follow

The stability testing is a crucial next step for IBEX011, as it aims to establish the shelf life and specifications necessary for potential future supply to regulated clinical research. This follows Filament's earlier announcement in September 2026 about planning a stability program for the drug candidate.

Regulatory context and U.S. support

These developments occur in the context of growing U.S. federal support for psychedelic research. An executive order issued in April 2026 highlighted ibogaine compounds as investigational therapies of interest, urging federal agencies to expedite research and facilitate access for eligible patients. Additionally, in October 2026, the FDA sought public input on the design and safety of early-phase ibogaine clinical trials.

Why it matters

Ibogaine, a Schedule I controlled substance in the United States, is not yet approved by the FDA or Health Canada for any indication. However, the completion of the new extraction and the initiation of stability testing for IBEX011 mark significant steps in the drug's development process. These efforts could potentially pave the way for future clinical research and therapeutic applications.

Rhelion Life Sciences' acquisition of Filament Health earlier in 2026 underscores its commitment to advancing psychedelic drug development, with a focus on both ibogaine and psilocybin.